Dermatoprotective activity of a combination of enoxifol with rexod in a reduced form the blood circulation in the skin in diabetes mellitus and hypercholesterinemia by Seletskaya, V. V. & Galenko-Yaroshevskii, P. A.
 Dermatoprotective activity of a combination of enoxifol with rexod in a reduced form the blood 
circulation in the skin in diabetes mellitus and hypercholesterinemia / V.V. Seletskaya, P.A. Galenko-
Yaroshevskii // Research result: pharmacology and clinical pharmacology. – 2017. – Vol. 3, №1 – P. 
32-48. 
32 
 
RESEARCH RESULT:  
PHARMACOLOGY AND CLINICAL PHARMACOLOGY 
 
 
 
 
UDC: 615.262:616.5-005]:616.379-008.64-092.9             DOI: 10.18413/2500-235X-2017-3-1-32-48 
 
Seletskaya V.V.,  
Galenko-Yaroshevskii P.A. 
DERMATOPROTECTIVE ACTIVITY OF A COMBINATION  
OF ENOXIFOL WITH REXOD IN A REDUCED FORM THE BLOOD 
CIRCULATION IN THE SKIN IN DIABETES MELLITUS  
AND HYPERCHOLESTERINEMIA 
 
Kuban State Medical University, 4 Sedin St., Krasnodar, 350063, Russia. 
e-mail: seleckaya.v@mail.ru 
 
Abstract. Experiments in rats showed that the 9-diethylaminoethyl-2-(3,4-dioxyphenyl)-imidazo-
[1,2-a]-benzimidazole dihydrobromide with the provisional name of enoxifol (0.94 – 15 mg/kg), 
rexod (recombinant human superoxide dismutase; 0.002 mg/kg) and especially their combination 
in  intravenous administration in a reduced blood circulation in the skin against the background of 
the normoglycemia and hyperglycemia induced by experimental (alloxanic) diabetes mellitus 
complicated by exogenous hypercholesterinemia have a pronounced dose-dependent 
dermatoprotective effect, which may be due to the activation of energy processes and increase the 
reserve capacity of the antioxidant support network and normalization of carbohydrate and lipid 
metabolism. A combination of enoxifol with alprostadil in normoglycemia increases significantly 
dermatoprotective activity of alprostadil and exceeds the activity of the combination of enoxifol 
with rexod. Under the conditions of normoxia and hypoxia, induced by sodium cyanide, and 
uncouple of oxidative phosphorylation, induced by 2,4-dinitrophenol, a combination of enoxifol 
with rexod, increases the viability of cultured osteoblasts and fibroblasts. Enoxifol (7.5 mg/kg, 
intravenously) has anti-inflammatory effect in edema induced by carrageenan, histamine, 
serotonin and Freund's complete adjuvant. Enoxifol (7.5 mg/kg, intravenously), rexod  
(0.02 mg/kg, intravenously) and especially its combination have a pronounced antiulcer action on 
steroid ulcers of a stomach, enoxifol activity compare poorly of the sea buckthorn oil (10 ml/kg 
intraperitoneally); the combination of enoximone with rexod much is much superior as enoxifol, 
rexod and sea buckthorn oil taken from separately.   
Key words: enoxifol, rexod, the combination of enoxifol with rexod, alloxanic diabetes mellitus, 
exogenous hypercholesterinemia. 
 
Introduction. 
Diabetes mellitus (DM), as one of the most 
severe socially significant diseases, often causes 
circulatory disorders in various organs and tissues, 
including a skin, inducing ischemic manifestations in 
them, and sometimes necrotic changes [1-7].  
Occurring in diabetes mellitus disturbances of 
carbohydrate, protein and lipid-metabolism cause 
accumulation in the body of insufficiently oxidized 
metabolites, the suppression of energy production in 
cells, and, as a consequence, often lead to organ and 
system lesions [8, 9].  
In the recent decades, molecular changes in the 
tissues in diabetes are widely studied, which helped 
to create some effective drugs: hypoglycemic, 
antihypoxic and antioxidants, as well as complex 
preparations [2, 10-15]. 
Currently available anti-diabetic drugs do not 
always meet the needs of practical health care [11, 
16, 17]. This is due to the fact that many anti-diabetic 
drugs can cause various side effects: allergic 
reactions, idiosyncrasy, hypoglycemia, and 
sometimes are ineffective. That’s why the 
development of new drugs and their combinations, 
which would have antihyperglycemic and 
cholesterol-lowering effects and did not show 
significant side effects is actually today [18-20]. 
A substance with laboratory code RU-185
1
  
(9-diethylaminoethyl-2-(3,4-dioxyphenyl)-imidazo-
[1,2-a]-benzimidazole dihydrobromide), called 
enoxifol and domestic drug rexod, constituting 
recombinant human superoxide dismutase,  deserve 
attention for that matter. 
                                                 
1
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Several studies showed that the basis of the 
protective action of enoxifol in acute and chronic 
hypoxia, cerebral ischemia and reperfusion injuries, 
as well as normalizing effect of this substance in 
disseminated intravascular coagulation (DIC) and 
DM is antioxidative activity and hemobiological 
properties [21, 22].  
Superoxide dismutase belongs to the group of 
antioxidant enzymes, represented by a family of 
metalloenzymes that catalyze the dismutation of the 
superoxide (O
2−
) radical. Together with catalase and 
other antioxidant enzymes, superoxide dismutase 
protects the body from constantly produced highly-
toxic oxygen radicals, catalyzes the dismutation of 
the superoxide (O
2−
) into oxygen and hydrogen 
peroxide. Thus, superoxide dismutase plays an 
important role in antioxidant defence of cells, or 
otherwise in contact with oxygen. 
It is known that diabetes mellitus leads to 
circulatory disorders and innervation of the basal 
layer of the skin, that leads to its atrophy and skin 
laxity. It leads to fissures and ulcerations of the skin, 
whereby the skin loses its protective function. Special 
type of diabetic skin lesions is lipoidica 
diabeticorum, as well as hyperpigmentation, 
erythema and lipoatrophy. The development of such 
disorders is related to the phenomenon of "oxidative 
stress", which consists in the formation in the blood 
of a large number of free radicals – oxygen molecules 
with a high ability to react. As a result of such 
reactions the cells of the body can be damaged. In 
healthy body the accumulation of the free radicals is 
regulated by antioxidants, which neutralize them. 
However, in diabetic patients, formulation of 
antioxidants is significantly reduced. One of the main 
antioxidants that show activity in the mentioned 
direction is superoxide dismutase. Specific activity of 
superoxide dismutase in antioxidant defence is to 
100,000 times higher of such traditional products, 
like vitamins A and E.  
Therefore, it seemed expedient to study the 
protective effects of enoxifol in combination with 
superoxide dismutase preparation – rexod with 
reduced blood circulation in the skin on the 
background of alloxan diabetes complicated by 
exogenous hypercholesterolemia (EHC). 
The research objective. To improve the survival 
of skin under condition of reduced blood circulation 
against the background of normo – and 
hyperglycemia and exogenous hypercholesterolemia 
by administration a combination of enoxifol with 
rexod; to perform in-depth preclinical study and to 
develop scientific and practical recommendations for 
its administration. 
Experimental procedure 
The study of dermatoprotective activity of a 
combination of enoxifol with rexod were performed 
according to methods described by A.V. Zelenskaya, 
P.A. Galenko-Yaroshevskii [26]. 
Experiments were performed on 676 male rats 
weighing 0.120 – 0.220 kg. 
The study of survival of tail tissues in reduced 
circulation against the background of 
normoglycemia was performed by the method 
described by A. V. Agadzhanova et al. [24]  
O. N. Stoyalova et al. [25].  
The study of viability of skin fold tissues of the 
back in circulatory disturbance against the 
background of normoglycemia was performed 
according to P.A. Galenko-Yaroshevskii, A.V. Tegai 
[27]. 
The study of viability of skin flap tissues of the 
anterior abdominal wall in reduced circulation 
(arterial insufficiency and venous stasis) against the 
background of normoglycemia, alloxanic diabetes 
mellitus and exogenous hypercholesterinemia was 
performed by the method described by  
A.V. Zelenskaya, P.A. Galenko-Yaroshevskii [26] и 
P.A. Galenko-Yaroshevskii, A.V. Tegai [27].The 
model of alloxanic diabetes mellitus was reproduced 
by a single intraperitoneal injection of alloxan at a 
dose of 135 mg/kg. Exogenous hypercholesterinemia 
was induced after 14 days of modeling of DM by 2 
week intragastric administration of the cholesterol 
emulsion (40 mg/kg) + vegetable oil (0.5 ml). The 
emulsion was added the ergocalciferol (12500 U/kg) 
to enhance peroxide stress [26].  
The study of carbohydrate composition and 
lipid of the blood against the background of 
alloxanic diabetes mellitus and exogenous 
hypercholesterinemia under the influence of 
enoxifol, rexod and their combinations was 
performed by using the analyzer "Konelab-30", 
Termoelektron firm. 
The study of the influence of enoxifol, rexod 
and their combination on the proliferation of 
cultured fibroblasts and osteoblasts of the skin and 
parietal bone respectively was performed according 
A.V. Zelenskaya, P.A. Galenko-Yaroshevskii [26]. 
For imaging cell cultures were stained methylene 
blue and photographed with the use of digital system 
"MekoS" [26].  
Antiphlogogenic effect was studied on the 
traditional model of acute paw inflammation 
induced carrageenan (1%), Freund's complete 
adjuvant (CAF), histamine (2 mM) and serotonin 
(0,1%) [28], which were administered in a volume of 
0.1 ml subplantarly in the right hind paw.  
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Antiulcer activity was investigated using a 
model of steroid-ethanol-induced gastric ulcer of 
the stomach [29]. Enoxifol was injected intravenous 
at the dose of 7.5 mg/kg (2 ml/kg of 0.1% solution). 
Warm (37° C) sea buckthorn oil, administered 
intragastrically (10 ml/kg), was used as reference 
drug. 
The study of the influence of enoxifol, rexod 
and their combination on values of energy 
metabolism, antioxidant system (AOS) and the 
activity of lysosomal enzymes of the skin fold of the 
back was performed according to the methods 
described by A.V. Zelenskaya, P.A. Galenko-
Yaroshevskii [26].  
Cytoprotective activity of enoxifol, rexod and 
their combination was studied in the experiments on 
the skin fold of the back. The skin samples after 
removal of the subcutaneous fat were homogenized at 
140000 rpm, extracting solution contained 0.45 of 
NaCl, 50 mM of Tris-buffer, pH 7.4. There were 
determined the concentrations of adenylic 
nucleotides, creatine phosphate (CP), the level of 
histamine and serotonin (fluorimetric method), 
enzymatic activity of alanine-aminotransferase 
(ALAT) and aspartate aminotransferase (ASAT) 
(using kit  "Bio-La-Test", "Lachema"), lactate 
dehydrogenase (LDH) (using test kit "Diachem"), 
NADH-cytochrome C-reductase (on the basis of the 
transition between the oxidized form and reduced 
form), lysosomal enzymes ribonuclease and 
concentration of cathepsin D, the rate of formation of 
superoxide anion, the activity of AOS (for the 
activity of SOD and catalase [26]).  
Statistical data processing was performed 
according to A.V. Zelenskaya, P.A. Galenko-
Yaroshevskii [26], using developed at the Department 
of pharmacology of Kuban state medical University a 
software for the computer IBM PC XT (USA). 
Results and evaluation 
A comparative study of histoprotective effect 
of enoxifol, rexod, alprostadil and their 
combinations in reduced circulation in the tail and 
the skin. The study of the histoprotective effect of 
enoxifol in experiments on the tails. it was found 
that on the 3rd day after the administration of 
enoxifol at the doses 15 and 7.5 mg/kg length of 
necrosis of the tails were 1.6 and 0.6%, respectively, 
versus 2.9% in control, and the administration of the 
drug at the doses of 3.75 and 0.94 mg/kg – 0.1 and 
0.3% versus 13.4% in the control group. The increase 
in survival of the tissues of the tail after 
administration of enoxifol at the doses of 15.0, 7.5, 
3.75 and 0.94 mg/kg for 3 days was 44.8, 79.3, 99.3 
and 97.8%, respectively (table. 1). 
Table 1 
The histoprotective effect of enoxifol in experiments  
on the rat tails (М ± m, n = 9) 
№ Drug 
Dose, 
mg/kg 
Length of the necrosis, % 
3rd day, а 7th day, b 
     
1 Control - 2.9 ± 2.5 70.9 ± 6.6 
 (normal 
saline 
solution) 
 
(0.4 ÷ 5.4) 
(55.8 ÷ 
86.0) 
    ра-b  < 0.001 
     
2 Enoxifol 15 1.6 ± 1.8 27.3 ± 8.9 
   (-0.2 ÷ 3.4) (6.7 ÷ 47.9) 
   [44.8] [61.5] 
   
р1-2 > 0.05 
р1-2 < 0.01.  
ра-b  < 0.01 
     
3 Enoxifol 7.5 0.6 ± 0.5 14.3 ± 6.8 
   (-0.5 ÷ 1.7) (-1.4 ÷ 30.0) 
   [79.3] [79.8] 
   р1-3 > 0.05.  
р2-3 > 0.05 
р1-3 < 0.001.  
р2-3 > 0.05 
    ра-b  > 0.05 
     
4 Control - 13.4 ± 5.8 72.6 ± 5.7 
 (normal 
saline 
solution) 
 
(-0.1 ÷ 
26.8) 
(63.0 ÷ 
89.4) 
    ра-b  < 0.001 
     
5 Enoxifol 3.75 0.1 ± 0.5 35.7 ± 10.0 
   
(-1.0 ± 1.2) 
(12.5 ÷ 
58.7) 
   [99.3] [50.8] 
   
р4-5 < 0.05 
р4-5 < 0.01.  
ра-b < 0.01 
     
6 Enoxifol 0.94 0.3 ± 0.4 55.4 ± 1.8 
   
(-0.5 ÷ 1.1) 
(51.3 ÷ 
59.5) 
   [97.8] [23.7] 
   р4-6 < 0.05.  
р5-6 > 0.05 
р4-6 < 0.01.  
р5-6 > 0.05 
    ра-b < 0.001 
     
Comment: within the brackets: parentheses –  95% 
confidence interval, square – surviving part of the skin flap 
(%) in comparison with necrotic part of the skin flap in the 
control, accepted as 100%. 
 
On the 7th day of the study with the 
administration of enoxifol at the doses of 15 and 7.5 
mg/kg length of the necrosis was 27.3 and 14.3%, 
respectively, versus 70.9% in control, whereas when 
the drug was administered at the dose of 3.75 and 
0.94 mg/kg the length of the necrosis was 35.7 and 
55.4% vs 72.6% of the control. The increase in 
survival of the tail tissues on the back of enoxifol 
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administration at the doses of 15.0, 7.5, 3.75 and  
0.94 mg/kg on the 7th day of the study amounted to 
61.5, 79.8, 50.8 and 23.7%, respectively.  
The comparative study of histoprotective 
effect of enoxifol, rexod and their combination. 
The experiments showed that on the 3rd day after 
intravenous administration of enoxifol (7.5 mg/kg), 
rexod (0.02 mg/kg) and their combination – enoxifol 
(7.5 mg/kg) + rexod (0.02 mg/kg) the length of the 
tail necrosis was 2.9, 6.6 and 0.5% respectively 
versus 11.2 and 33.3% at the first and second 
controls. The survival of tissues on the back of 
administration of enoxifol, rexod and their 
combination amounted to 74.1, 41.1 and 98.5%, 
respectively (Figure 1). 
 
 
 
Figure 1. The influence of intravenous administration of enoxifol, rexod and their combination on the survival  
of the tail tissues in the reduced blood circulation on the 3rd and 7th day of the study 
 
The necrosis length of the tail on the 7th day 
was 16.4 and 53.4 and 2.6%, respectively, versus 
72.4 and 72.0% in the first and second controls. The 
increase in survival of the tail tissues on the back of 
administration of enoxifol, rexod and their 
combination was 77.3, 26.5 and 96.4%, respectively.  
A comparative study of the dermatoprotective 
effect of enoxifol, rexod and their combination in 
ischemic skin fold of the back. It was found that after 
a single intravenous dosing of enoxifol (7.5 mg/kg), 
rexod (0.02 mg/kg) and their combination – enoxifol 
(7.5 mg/kg) + rexod (0.02 mg/kg) on the 3rd day of 
the experiment, the necrosis length of the skin fold of 
the back was 9.6, 8.2 and 11.2% respectively versus 
22.3% in control. The survival rate of the skin equal 
57.0, 63.2 and 49.8%, respectively. 
On the 7th day of the study necrotic part of the 
skin fold was 41.5, 54.2 and 31.6% respectively, 
while in control it was 71.2%. The survival of the 
skin fold was 41.7, 23.9 and 55.6%, respectively 
(Figure 2). 
With 7-fold intravenous dosing of enoxifol, 
rexod and their combination on the 3rd day of the 
experiment, the necrosis length of the skin fold of the 
back was 11.4, 16.6 and 1.8%, respectively, versus 
21.0% of the control. The survival rate of the skin is 
equal to 45.7, 21.0 and 91,0%, respectively.  
On the 7th day of the study necrotic part of the 
skin fold amounted to 30.6, 58.4 and 3.8%, 
respectively, while in control it was 92.9%. The 
survival of the skin fold was equal 67.0, 37.1 and 
95.9%, respectively (Figure 2). 
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Figure 2. The influence of intravenous administration (single and sevenfold) of enoxifol, rexod and their combination  
on the survival of the ischemic skin fold of the back on the 3rd and 7th day of the study 
 
A comparative study of the dermatoprotective 
effect of enoxifol, rexod, alprostadil and their 
combination on the skin flap of the anterior 
abdominal wall in reduced circulation (arterial 
insufficiency and venous stasis). Under condition of 
normoglycemia and arteriovenous failure induced by 
occlusion of the arteries and veins of the skin flap on 
one side, with a single intravenous administration of 
enoxifol (7.5 mg/kg), rexod (0.02 mg/kg), the 
combination of enoxifol (7.5 mg/kg) + rexod (0.02 
mg/kg), alprostadil (0.00415 mg/kg) and combination 
of enoxifol (7.5 mg/kg) + alprostadil (0,00415 
mg/kg), the necrosis area in the skin flap on the 3rd 
day of the experiment was 20.1, 26.2, 14.1, 15.5 and 
9.9%, respectively, versus 34.9% in the control 
(figure 3). The survival rate of skin was equal to 42.4, 
24.9, 59.6, 55.6 and 71.6 %, respectively. On the 7th 
day necrosis in the skin flap under the effect of the 
drugs was 40.9, 39.3, 37.5, and 10.5% respectively, 
versus 65.7% in the control. The survival of the skin 
flap was equal to 37.7, 40.2, 42.9, 65.1 and 84.0%, 
respectively. On the 10th day of the experiment 
necrotic part of the skin flap reached 45.7, 62.2, 40.4, 
28.1 and 12.0% respectively, versus 82.5% in the 
control. At that there was survived 44.6, 24.6, 51.0, 
65.9 and 85.9% of the skin, respectively. 
 
Figure 3. The influence of the single intravenous administration of enoxifol (E), rexod (R), combination enoxifol + rexod 
(E+R), alprostadil (A) and combination enoxifol + alprostadil (E+A) on the survival of the skin flap of the anterior abdominal 
wall in reduced circulation (arterial insufficiency and venous stasis) on the 3
rd
, 7
th
 and 10
th
 days of the study. 
Keys: here and in figures 4 and 5: * – 7th and 10th days statistically significantly in comparison with 3rd day, ° – 10th day 
statistically significantly in comparison with 7
th
 day 
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We haven’t studied a combination rexod (0.02 
mg/kg) + alprostadil (0.00415 mg/kg) because the 
work of A. V. Zelenskaya, P. A. Galenko-
Yaroshevskii [26] showed that this combination had 
no dermatoprotective activity. 
Under condition of normoglycemia and 
arteriovenous failure induced by ligation of the 
arteries and veins of the skin flap on one side, with a 
repeated intravenous administration of enoxifol  
(7.5 mg/kg), rexod (0.02 mg/kg), the combination 
enoxifol (7.5 mg/kg) + rexod (0.02 mg/kg), 
alprostadil (0.00415 mg/kg) and combination 
enoxifol (7.5 mg/kg) + alprostadil (0,00415 mg/kg), 
the necrosis area in the skin flap on the 3
rd
 day of the 
experiment was 20.2, 23.6, 16.1, 13.3 and 5.2%, 
respectively, versus 38.1% in the control. The 
survival rate of the skin was equal to 47.0, 38.1, 57.7, 
65.1 and 56.4%, respectively. On the 7
th
 day, necrosis 
in the skin flap was 38.1, 40.2, 36.8, 26.8 and 7.4%, 
respectively, versus 68.7% in the control group. The 
increase in survival of the skin flap was 44.5, 41.5, 
46.4, 61.0 and 89.2%, respectively. On the 10
th
 day 
the skin necrosis was equal 46.9, 62.3, 45.4, 33.2 and 
9.5%, respectively, versus 80.8% of the control. The 
survival rate of the skin flap was equal 42.0, 22.9, 
43.8, 58.9 and 88.2%, respectively (figure 4). 
 
 
Figure 4. The influence of the sevenfold intravenous administration of enoxifol (E), rexod (R), combination enoxifol + rexod 
(E+R), alprostadil (A) and combination enoxifol + alprostadil (E+A) on the survival of the skin flap of the anterior abdominal 
wall in reduced circulation (arterial insufficiency and venous stasis) on the 3
rd
, 7
th
 and 10
th
 days of the study 
 
 
A study of the dermatoprotective effect of 
combination of enoxifol with rexod in experimental 
diabetes mellitus (EDM), complicated by exogenous 
hypercholesterinemia, in experiments on the skin 
flap of the anterior abdominal wall in case of 
partial arteriovenous failure. It was found that 
administration of the combination enoxifol (7.5 
mg/kg) + rexod (0.02 mg/kg) against the background 
of normoglycemia, the necrosis area of the anterior 
abdominal wall in case of partial arteriovenous 
failure at 3
rd
, 7
th
 and 10
th
 days was 9.8, 32.0 and 
38.0% vs 28.8, 51.9 and 68.0% in controls. The 
survived part of the skin flap was equal 66.0, 38.3 
and 44.1%, respectively. 
When intravenous administration of a 
combination enoxifol (7.5 mg/kg) + rexod (0.02 
mg/kg) for 14 days against the background of EDM 
complicated by exogenous hypercholesterinemia, on 
the 3
rd
, 7
th
 and 10
th
 days the necrosis area of the skin 
flap was equal 6.9, 23.2 and 23.2% versus 33.3, 63.2 
and 82.8% in contros. The survived part of the skin 
was 79.3, 66.3 and 72.0, respectively. 
In the control experiments (normal saline 
solution against the background of EDM and 
exogenous hypercholesterinemia) the necrosis area of 
the skin flap in comparison with group of intact 
animals (administration normal saline solution only) 
on the 3
rd
, 7
th
 and 10
th
 days statistically significantly 
decreased by 4.5, 11.3 and 14.8%, respectively 
(figure 5). 
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Figure 5. The influence of the repeated intravenous administration of combination enoxifol + rexod on the survival of the skin 
flap of the anterior abdominal wall in case of partial arteriovenous failure against the background of normoglycemia and 
exogenous hypercholesterinemia on the 3
rd
, 7
th
 and 10
th
 days of the study 
 
Biochemical blood analysis found that the blood 
glucose in the group of animals with EDM and 
exogenous hypercholesterinemia amounted to 9.54% 
vs of 5.62% in the intact group, that is, the 
experimental rats were increased the level of the 
blood glucose in 1.7 times. In the case of 
combination enoxifol + rexod against the background 
of EDM and exogenous hypercholesterinemia the 
level of the blood glucose amounted to 2.67 mM/l 
versus 9.54 mM/l in the control group, that is, the 
blood glucose decreased in 3.6 times. When 
adminisrtating the combination enoxifol + rexod in 
intact animals, the level of the blood glucose was 
2.70 mM/l versus 5.62 mM/l in control; the level of 
the blood glucose decreased in 2.1 times (figure 6). 
The total cholesterol in the control 
(normoglycemia) was 1.48 mM/l and in the group of 
animals with EDM and exogenous 
hypercholesterinemia it was 2.32 mM/l, that is, in the 
latter case, the level of total cholesterol increased in 
1.6 times. When administration the combination 
enoxifol + rexod (aginst the background of EDM and 
exogenous hypercholesterinemia) the level of total 
cholesterol was 1.80 mM/l versus 1.48 mM/l in the 
control (intact animals), that is, there was a decrease 
in the level of total cholesterol in 1.2 times. Against 
the background of normoglycemia in experimental 
rats it level (1.43 mM/l) did not differ (1.48 mM/l) 
from control. 
Triglycerides level in control (normoglycemia) 
was 0.71 mM/l and in the group of animals with 
EDM and exogenous hypercholesterinemia it was 
3.17 Mm/l, i.e. in the latter case, it had increased in 
4.5 times. When administration the combination 
enoxifol + rexod (aginst the background of EDM and 
exogenous hypercholesterinemia) the level of 
triglycerides was 2.30 mM/l vs. 3.17 mM/l in the 
corresponding control, i.e., it decreased in 1.4 times. 
Under condition of normoglycemia combination 
enoxifol + rexod (0.63 mM/l) had no significant 
effect on triglycerides in comparison with the control 
group (0.71 mM/l). 
β-lipoproteins (β-LP) in control 
(normoglycemia) was 5.93 mM/l, and in the group of 
animals with EDM and exogenous 
hypercholesterinemia it was 11.56 mM/l, i.e. in the 
latter case the level of β-LP was increased in 1.9 
times. The level of β-LP after administration the 
combination enoxifol + rexod in the group of animals 
with EDM and exogenous hypercholesterinemia was 
equal to 5.90 mM/l versus 11.56 mM/l in the 
corresponding control, i.e. there was a decrease of it 
in the former case in 2.0 times. Under condition of 
normoglycemia combination enoxifol + rexod  
(5.86 mM/l) had no significant effect on the β-LP 
level in comparison with the control group  
(5.93 mM/l). 
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Figure 6. The influence of the combination enoxifol + rexod (E + R, 7.5 + 0.02 m/kg) (intravenous administration for 14 days) 
on the level of the glucose, total cholesterol, triglycerides, high density lipoproteins (HDL) and β-lipoproteid aginst  
the background of normoglycemia, EDM and exogenous hypercholesterinemia 
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The level of high density lipoproteins (HDL) in 
control (normoglycemia) was 2.34 mM/l and in the 
group of animals with EDM and exogenous 
hypercholesterinemia it was 0.55 mM/l, i.e. in the latter 
case, the level of HDL decreased in 4.3 times. The HDL 
level in consequence of administration of the 
combination enoxifol + rexod against the background of 
EDM and exogenous hypercholesterinemia was equal 
to 1.31 mM/l vs 0.55 mM/l in the corresponding 
control, i.e. there was an increase of HDL level in 2.4 
times. Under condition of normoglycemia, combination 
enoxifol + rexod (2.07 mM/l), had no significant effect 
on the HDL level in comparison with the control group 
(2.34 mM/l) (figure 6). 
A study of some of the parties in an mechanism 
of dermatoprotective effect of enoxifol, rexod and its 
combination. The influence of enoxifol, rexod and its 
combination on the viability of the cultured fibroblasts 
and osteoblasts against the background of normoxia, 
hypoxia and uncouple of oxidative phosphorylation. 
The influence on the proliferative activity of FB. It was 
found that in the control studies, the optical density of 
the cultivated FB samples was 2140.0 conditional units 
(c.u.). The administration of enoxifol at a concentration 
of 0.01 and 0.001 mg/ml, rexod at a concentration of 
0.0001, 0.0005 and 0.001 mg/ml, the combination of 
enoxifol (0.01, 0.001 and 0.01 mg/ml) + rexod (0.0001, 
0.0005 and 0.001 mg/ml) the optical density of the 
samples was equal 2284.0 and 2325.0, 1794.0, 1882.0 
and 1982.0, 2284.0, 2357.0 and 1982.0 c.u., 
respectively; there was no statistically significant 
differences in comparison with control. 
A study of the influence of enoxifol, rexod and its 
combination under condition of hypoxia of FB caused 
by 0.2 mM NaCN found that in control (administration 
NaCN only) the optical density of the cultivated FB 
samples was 1139.0 c.u.; it was statistically significant 
(p < 0.05) in comparison with intact FB. The 
administration of enoxifol, rexod and its combination in 
the above concentrations against the background of 
NaCN as in the previous series of experiments did not 
cause statistically significant changes of the optical 
density of the cultivated FB samples in comparison with 
the control (NaCN): values of the optical density of the 
cultivated FB samples were equal 1448.0 and 1321.0, 
935.0, 994.0 and 1050.0, 995.0, 1324.0 and 1388.0 c.u, 
respectively. 
A study of the influence of enoxifol, rexod and 
its combination on the proliferative activity of FB 
against the background of uncouple of oxidative 
phosphorylation by dinitrophenol found that in the 
control (administration of dinitrophenol only), the 
viability of FB statistically significantly decreased 
and amounted 540.0 c.u. (p < 0.05). 
The administration of enoxifol, rexod and 
especially its combination at the selected concentrations 
the optical density of the cultivated FB samples 
significantly (p < 0.05 in all experimental groups) 
increased, accounting for 778.0 and 637.0, 763.0, 725.0 
and 751.0, 922.0, 804.0 and 796.0 c.u., respectively. 
The influence on the proliferative activity of 
osteoblasts (OB). Performed experiments showed that 
in the control the optical density of the cultivated OB 
samples was 1464.0 c.u. Administration of enoxifol at 
the concentrations of 0.01 and 0.001 mg/ml, rexod at 
the concentrations of 0.0001, 0.0005, 0.001 mg/ml, the 
combination enoxifol (0.01, 0.001 and 0.01 mg/ml) + 
rexod (0.0001, 0.0005 and 0.001 mg/ml) didn’t show 
significant of the optical density of the cultivated OB 
samples in comparison with the control. The optical 
density of the cultivated OB samples was equal to 
1726.0 and 1621.0, 1296.0, 1425.0 and 1646.0, 1695.0, 
1677.0 and 1554.0 c.u., respectively.   
Administration of the studied drugs and its 
combination in the above concentrations against the 
background of hypoxia of OB induced by 0.2 mM 
NaCN, found that the proliferative activity of OB 
under the influence of enoxifol (1327.0 and 1256.0 
c.u.) and rexod (1171.0, 1168.0 and 1057.0 c.u.), did 
not change significantly in comparison with control 
(1138.0 c.u.), whereas administration of the 
combination of enoxifol (0.01 and 0.001 mg/ml) + 
rexod (0.0001 and 0.0005 mg/ml) statistically 
significantly increased the optical density of the 
cultivated OB samples (1486.0 and 1439.0 c.u., 
respectively). It should be noted that with increase in 
combination enoxifol (0.01 mg/ml) + rexod the 
concentration of the latter to 0.001 mg/ml the 
proliferative activity of OB samples (1236.0 c.u.) did 
not differ significantly from control. 
The study of the influence of enoxifol, rexod and 
its combination on the proliferative activity of OB 
against the background of uncouple of oxidative 
phosphorylation by dinitrophenol (0.5 mM) found that 
in the control (administration of dinitrophenol only), the 
viability of OB statistically significantly decreased 
(818,0 c.u.) in comparison with intact OB. The 
administration of researched drugs and its combination 
in the above experimental conditions showed that the 
optical density of the cultivated OB samples of 
enoxifol, taken at a concentration of 0.01 mg/ml, 
statistically significantly increased (1092.0 c.u., p < 
0.05), but with increasing concentration (up to 0.001 
mg/ml) it decreased (914.0 c.u.) and did not differ from 
control. A similar situation occurred when 
administrating rexod: in its concentrations of 0.0001 
and 0.0005 mg/ml the OB viability a statistically 
significantly increased in comparison with control 
(dinitrophenol), the optical density of the cultivated OB 
samples was respectively equal to 1234.0 and 1084.0 
c.u., while with increasing concentration up to 0.001 
mg/ml, the optical density of the cultivated OB samples 
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did not differ from control. The combination of enoxifol 
with rexod, in which the first drug was administered at a 
concentration of 0.01 mg/ml, and the second – 0,0001 
mg/ml increased the cultured OB viability, while the 
optical density of the cultivated OB samples was 1136.0 
c.u. Increase in the mentioned combination the 
concentrations of enoxifol (0.001 and 0.01 mg/ml) and 
rexod (0.0005 and 0.001 mg/ml) had no significant 
influence on the OB proliferative activity in comparison 
with control. The optical density of the cultivated OB 
samples was 969.0 and 1056.0 c.u., respectively. 
The influence of enoxifol on acute 
inflammation. It was found, that intravenous 
administration of enoxifol at the dose of 7.5 mg/kg 
takes anti-inflammatory action in the models of acute 
exudative edema induced by different phlogogens: 
carrageenan, Freund's complete adjuvant (CFA), 
histamine and serotonin. Thus, the inhibition of 
edema in different series of experiments under the 
influence of the drug was: carragenine – 42.8%, CFA 
– 60.3% and histamine – 35.0%. While the first two 
models of edema enoxifol lost anti-inflammatory 
activity to reference drugs – indomethacin  
(10 mg/kg) and, to a lesser extent, piroxicam  
(20 mg/kg); the inhibition of inflammation by lasts 
was 70.0 and 68.1%, respectively (figure 7). 
 
  
  
Figure 7. The influence of enoxifol (E), indomethacin (In) and piroxicam (Pir) on the acute edematisation, induced by 
carrageenan, CFA, serotonin and histamine. 
 
Modeling of the inflammatory edema induced 
by serotonin, the measurement of paw edema after 45 
min and 24 h after induction of edema showed that 
the anti-inflammatory effect in animals treated with 
enoxifol, after 1 day not only kept, but were even 
more pronounced in comparison with the short 
observation period (45 min); inhibition of 
inflammation in the first case was 51.0%, and in the 
second – 81.1% (figure 7). 
A study of antiulcer activity of enoxifol, rexod 
and its combination in steroid-ethanol damage of a 
gastric mucosa. In the control studies (single 
intragastric administration of prednisolone at a dose of 
20 mg/kg in 80% ethanol) animal gastric mucosa was 
hyperemic, hemorrhages, pronounced vascularization, 
significant erosions and ulcers were observed across the 
mucosa. Micromorphology showed polymorphocellular 
infiltration with predominance of neutrophils of a 
lamina propria of the mucosa and submucosa, having an 
essentially focal character. There were leukopedesis, 
paravasal granulocytes. Mucoid cells spread more 
deeply. There was observed the desquamation of 
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surface mucous cells, typical for ulcerous erosive 
involvement of the stomach with pronounced burned-
out. The ulcers area was on average of 6.4 mm
2 
or 4.7 
ulcerous erosive involvement in one animal (figure 8). 
 
Figure 8. Antiulcer activity of enoxifol (E), rexod (R), sea buckthorn oil (SBO) ad combination enoxifol + rexod (E + R) in 
steroid-ethanol damage of a gastric mucosa. 
 
Under the influence of the intravenous 
administration of enoxifol (7.5 mg/kg) and, to a 
greater extent, rexod (0.02 mg/kg) there was 
observed statistically significant (compared to 
control) reduction of the ulcers area of the gastric 
mucosa, that was 1.5 and 0.4 mm
2
, respectively. 
While micromorphology of the gastric mucosa did 
not significantly differ from it in control. As for 
antiulcer activity of SBO, taken as the reference drug, 
under its influence ulcers area of the gastric mucosa 
was equal to 1.1 mm
2
 and statistically significantly 
differed from the control. Micromorphological 
changes were focal diffuse: granulocytes dominated 
among the free cellular elements, there were detected 
intraepithelial isolated leucocytes, glandular 
epithelium and surface mucous cells had signs of 
dystrophy and vacuolization (figure 8). 
Intravenous administration of the combination 
enoxifol + rexod (E + R) took a pronounced 
gastroprotective effect: the ulcers area of the gastric 
mucosa was equal to 0.08 mm
2
. Micromorphologically 
there wasn’t noted pathological changes typical for 
ulcerous involvement of the stomach, such as 
pronounced edema of the mucous and submucous, 
ganglia of myenteric nervous plexus. A gastric mucosa 
angioarchitecture has not been disrupted. Infiltrative 
changes were diffuse.  
On antiulcer activity the studied drugs can be 
arranged in the following descending range: enoxifol 
+ rexod > rexod > SBO > enoxifol. 
A study of the influence of enoxifol, rexod and 
its combination on the indices of intensity of the 
necrotic process, antioxidant defence and energy 
metabolism in the skin fold of the back. The 
influence on the indices of intensity of the necrotic 
process in ischemic skin. It was found, that there 
were statistically significantly increase the 
concentration of creatine phosphokinase (CPK) in the 
blood (263.4%) and activity of LDH, ALAT and 
ASAT by 64.7, 49.2 and 40.9%, respectively in the 
control group of animals (ischemic skin) in 
comparison with intact group; killing titer increased 
by 156.5% (table 2). 
Intraperitoneal administration of enoxifol at a 
dose of 7.5 mg/kg significantly decreased the 
concentration of CPK by 37.2% and LDH activity by 
21.4% in blood of experimental groups of animals in 
comparison with the control group. The activity of 
ALAT and ASAT did not change significantly. 
Killing titer decreased by 33.3% (table 2). 
Administration of rexod (0.02 mg/kg) in the 
adopted experimental conditions significantly 
decreased the concentration of CPK by 38.5% in 
comparison with control group of animals. The 
activity of ASAT was reduced by 10.6%. Other 
indices (LDH, ALAT and the killing titer) did not 
change significantly (table 3). 
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Table 2 
Antinecrotic effect of enoxifol (7.5 mg/kg) in ischemic skin (M ± m, n = 8) 
Index Intact group 
Ischemic skin 
Control group Experimental group 
CPK, mIU/L 
7.1 ± 0.2 
 
25.8 ± 1.6*** 
(263.4) 
16.2 ± 0.6*** 
128.2/-37.2 
LDH, mM NAD/mg of 
protein per min 
0.17 ± 0.02 
0.28 ± 0.01*** 
(64.7) 
0.22 ± 0.01* 
29.4/-21.4 
ALAT, mmM/ml 1.77 ± 0.20 
2.64 ± 0.18** 
(49.2) 
2.32 ± 0.12* 
31.1/-12.1 
ASAT, mmM/ml 1.15 ± 0.04 
1.62 ± 0.10*** 
(40.9) 
1.53 ± 0.20 
33.0/-5.6 
killing titer, CPK/ASAT 6.2 ± 0.3 
15.9 ± 1.8*** 
(156.5) 
10.6 ± 1.4** 
71.0/-33.3 
*р < 0.05, **р < 0.01, ***р < 0.001 in comparison with intact group; р < 0.05, р < 0.001 in comparison with control 
group. 
Comment: 1. Here and in tables 3-7: 1. within the brackets – indices in percentage terms in relation to intact group. 2. in 
the numerator – indices in percentage terms in relation to intact group, in the denominator – indices in percentage terms in 
relation to control group. 
Table 3 
Antinecrotic effect of rexod (0.02 mg/kg) in ischemic skin (M ± m, n = 7) 
Index Intact group 
Ischemic skin 
Control group Experimental group 
CPK, mIU/L 
7.7 ± 0.4 
29.9 ± 2.2*** 
(288.3) 
18.4 ± 0.8*** 
139.0/-38.5 
LDH, mM NAD/mg of protein 
per min 
0.19 ± 0.01 
0.32 ± 0.02*** 
(68.4) 
0. 26 ± 0.02* 
36.8/-18.7 
ALAT, mmM/ml 
1.96 ± 0.10 
2.96 ± 0.19*** 
(51.0) 
2.69 ± 0.11*** 
37.2/-9.1 
ASAT, mmM/ml 
1.19 ± 0.05 
1.70 ± 0.04*** 
(42.9) 
1.52 ± 0.07* 
27.7/-10.6 
killing titer, CPK/ASAT 
6.6 ± 0.4 
16.3 ± 2.6*** 
(147.0) 
12.8 ± 1.5** 
93.9/-21.5 
*р < 0.01, **р < 0.002, ***р < 0.001 in comparison with intact group; р < 0.05, р < 0.01, р < 0.001  in comparison 
with control group. 
 
Administration of combination of enoxifol  
(7.5 mg/kg) with rexod (0.01 mg/kg) decreased the 
concentration of CPK by 38.8% in comparison with 
the control group of animals. The activity of LDH, 
ALAT and ASAT decreased by 30.6, 23.7 and 31.6% 
respectively. Killing titer did not change significantly 
(table 4). 
Table 4 
Antinecrotic effect of enoxifol (7.5 mg/kg) + rexod  (0.02 mg/kg) in ischemic skin (M ± m, n = 8) 
Index Intact group 
Ischemic skin 
Control group Experimental group 
CPK, mIU/L 
 
7.9 ± 0.3 
28.6 ± 1.8** 
(262.0) 
17.5 ± 0.5** 
121.5/-38.8 
LDH, mM NAD/mg of 
protein per min 
0.18 ± 0.02 
0.36 ± 0.02** 
(100.0) 
0.25 ± 0.01* 
38.9/-30.6 
ALAT, mmM/ml 1.87 ± 0.10 
3.80 ± 0.20** 
(103.2) 
2.90 ± 0.10** 
55.1/-23.7 
ASAT, mmM/ml 1.21 ± 0.06 
1.90 ± 0.20* 
(57.0) 
1.30 ± 0.10 
7.4/-31.6 
killing titer, CPK/ASAT 6.5 ± 0.4 
15.1 ± 1.5** 
(132.3) 
13.4 ± 1.9* 
106.2/-11.3 
*р < 0.01, **р < 0.001in comparison with intact group; р < 0.02, р < 0.002, р < 0.001  in comparison with control 
group. 
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It should be noted that of all the studied 
indicators of the intensity of the necrotic process, 
only the ASAT activity in the blood of experimental 
group of animals was almost comparable to it of the 
intact group when administration of enoxifol and its 
combination with rexod. 
The influence on metabolic processes in 
ischemic skin flap:  
– the influence of enoxifol on the indices of the 
antioxidant defense and energy metabolism in the 
ischemic skin. Previously, in our laboratory in the study 
of the influence of enoxifol on the system of energy 
supply, the antioxidant defense and the activity of 
lysosomes (histamine, cytochrome C, NAD·H –
cytochrome of C-reductase, NAD
+, NAD·H, NAD+/ 
NAD·H, NAD+ + NAD·H, SOD, Cu, Zn-SOD, 
catalase, oxyproline, cathepsin D, ribonuclease, alkaline 
phosphatase (ALP), β-galactosidase and the total 
nitrogen content) of the skin flap (on pedicle) there was 
showed the mechanism of dermatoprotective effect of 
enoxifol (RU-185) may be due to its ability to rectify 
the free-radical oxidation processes, to activate 
glycolysis and the reactions of the respiratory chain; to 
influence the arachidonic acid metabolism, synthesis 
and breakdown of proteins and nucleic acids and 
associated with this, the activity of lysosomal enzymes; 
– the influence of rexod on the indices of the 
antioxidant defense and energy metabolism in the 
ischemic skin. We have found that in the control 
group of animals (with a simulated skin ischemia) 
there was a statistically significant increase the rate 
formation of O
2- 
(RFO
2-
) (by 93.9%), 
malondialdehyde (MDA) (by 8.0%), while SOD 
activity was decreased (by 25.9%); the glutathione 
peroxidase (GP) and catalase activity did not change 
significantly (table 5). 
Intraperitoneal administration of rexod at a dose 
of 0.02 mg/kg in homogenates of the ischemic skin of 
the experimental group of animals statistically 
significant increased (by 70% and 24.0% 
respectively) the activity of SOD and GP, while the 
concentration of MDA was reduced (by 10.6%) in 
comparison with control group. RFO
2- 
and catalase 
activity did not change significantly (table  
6). 
Table 5 
The influence of rexod (0.02 mg/kg) on the antioxidant defense in the ischemic skin (M ± m, n=7) 
Index Intact group 
Ischemic skin 
Control group Experimental group 
RFO
2-, µM/mg of protein  min 
33.0 ± 5.0 
64.0 ± 6.0*** 
(93.9) 
66.0 ± 6.0*** 
100.0/3.1 
SOD, U/mg of protein  min 
0.27 ± 0.01 
0.20 ± 0.01**** 
(-25.9) 
0.34 ± 0.02** 
25.9/70.0 
GP, nM NAD/mg of protein 
2.4 ± 0.1 
2.5 ± 0.1 
(4.2) 
3.1 ± 0.2** 
29.2/24.0 
Catalase, nM Н2О2/mg of protein  
min 
71.0 ± 2.0 
64.0 ± 4.0 
(-9.9) 
72.0 ± 4.0* 
1.4/12.5 
MDA, µM/mg of protein 
0.87 ± 0.01 
0.94 ± 0.03* 
(8.0) 
0.84 ± 0.02 
-3.4/-10.6 
*р < 0.05, **р < 0.01,***р < 0.002, ****р < 0.001 in comparison with intact group; 
р < 0.02, р < 0.001 in comparison with control group.  
 
 
In the study of the influence of rexod on the 
energy state of the ischemic skin, it was found that in 
the control group of animals the concentration of 
ADP and lactate in homogenates statistically 
significantly increased (by 13.9 and 47.6%, 
respectively), while the activity of succinate 
dehydrogenase (SDH) decreased (by 9.6%), LDH 
increased (68.4%) in comparison with intact group. 
Other indices (cytochrome C, AMP, NAD
+, NAD·H, 
pyruvate and lactate/pyruvate ratio) did not change 
significantly (table 6). 
Intraperitoneal administration of rexod at the 
dose of 0.02 mg/kg in homogenates of the skin of the 
experimental group of animals increased the content 
of NAD+, NAD+/NAD•H ratio, coenzyme Q10 (by 
15.5, 20.5 and 57.2%, respectively), and decreased 
the concentration of lactate (by 15.6%) in comparison 
with control group. As for the content of cytochrome 
C, ATP, ADP, AMP, AP, NAD•H, pyruvate, 
lactate/pyruvate ratio and the activity of SDH and 
LDH, it did not change significantly (table 6). 
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Table 6 
The influence of rexod (0.02 mg/kg) on the system  of energy supply in the ischemic skin (M ± m, n=7) 
Index Intact group 
Ischemic skin 
Control group Experimental group 
Cytochrome С, µM/mg 
0.99 ± 0.04 
0.92 ± 0.01 
(-7.1) 
0.92 ± 0.01 
-7.8/0.0 
ATP, µM/g 3.51 ± 0.04 
 
2.54 ± 0.10**** 
(-27.6) 
2.71 ± 0.11**** 
-22.8/6.7 
ADP, µM/g 
1.44 ± 0.03 
1.64 ± 0.03**** 
(13.9) 
1.60 ± 0.02**** 
11.1/-2.4 
АМP, µM/g 
0.53±0.04 
0.65±0.04 
(22.6) 
0.69±0.04** 
30.2/6.2 
AP, µM/g 
4.2 ± 0.1 
3.1 ± 0.2*** 
(-26.2) 
3.6 ± 0.2*
 
-14.3/16.1 
NАD
+
, µM/g 
2.75 ± 0.05 
2.0 ± 0.1 
(-27.3) 
2.31 ± 0.06****
 
-16.0/15.5 
NАD
+
·Н, µM/g 
2.72 ± 0.06 
2.75 ± 0.1 
(1.1) 
2.6 ± 0.08 
-4.4/-5.5 
NАD
+
/ NАD·Н 
0.99 ± 0.02 
0.73 ± 0.05*** 
(-26.3) 
0.88 ± 0.02***
 
-11.1/20.5 
Coenzyme Q10, mcg/g  1612.0 ± 68.0 
927.0 ± 54.0 **** 
(-42.5) 
1463.0 ± 67.0
 
-9.2/57.2 
Lactate, mcg/g 
351.0 ± 24.0 
518.0 ± 21.0**** 
(47.6) 
437.0 ± 22.0*
 
24.5/-15.6 
Pyruvate, mcg/g 
5.4 ± 0.3 
6.7 ± 0.6 
(24.1) 
6.3 ± 0.4 
16.7/-6.0 
Lactate / Pyruvate 
66.0 ± 6.0 
82.0 ± 9.0 
(24.2) 
75.0 ± 6.0 
13.6/-8.5 
SDH, mcg of formazan /mg of 
protein  min 
5.2 ± 0.2 
4.7 ± 0.1* 
(-9.6) 
4.7 ± 0.1* 
-9.6/0.0 
LDH, nM NAD/mg of protein  
min 
0.19 ± 0.01 
0.32 ± 0.02**** 
(68.4) 
0.26 ± 0.02***
 
36.8/-18.7 
*р < 0.05, ** р < 0.02,*** р < 0.01, **** р < 0.001 in comparison with intact group; 

р < 0.05, 

  р < 0.02, 

 р < 0.001 in 
comparison with control group. 
 
- the influence of combination of enoxifol with 
rexod on indices of energy supply, the antioxidant 
defense and lysosomal activity in ischemic skin. It 
was found that in the control group of animals 
(ischemic skin fold of the back), there was observed a 
statistically significantly decrease (by 79.6, 34.1, 
34.1, 21.3, 36.3, 13.3 and 16.1% respectively) the 
content in the skin homogenates of ATP, ATP/AMP 
ratio, AP, cytochrome C, coenzyme Q10, the activity 
of SDH and consolidated figures for NAD
+
 + 
NAD·H, while the concentration of LDH increased; 
the content of ADP, AMP, pyruvate and the 
lactate/pyruvate ratio, the activity of NAD·H-
cytochrome of C-reductase, NAD
+, NAD·H, 
NAD
+/NAD·H ratio did not change significantly in 
comparison with intact group (table 7). 
Intraperitoneal administration of the combination 
enoxifol (7.5 mg/kg) + rexod (0.01 mg/kg) statistically 
significantly increased the content of AP, coenzyme 
Q10 and consolidated figures for NAD+ + NAD•H 
(24.1, 30.7 and 14.6%, respectively) in the ischemic 
skin homogenates of the experimental group of animals 
in comparison with control group, while lactate 
concentration decreased (by 19.9%). Other indices 
(ATP, ADP, AMP, ATP/AMP ratio, cytochrome C, 
pyruvate, lactate/pyruvate ratio and the activity of SDH, 
NAD•H-cytochrome of C-reductase, NAD+, NAD H 
and NAD+/NAD•H ratio) were unchanged (table 7). 
Indices of the antioxidant defense and a condition 
of the hydrolytic function of lysosomes also changed: in 
the control group of animals (with the skin ischemia) 
there were increased RFO
2-
, activity of the catalase, 
cathepsin D and alkaline phosphatase (by 185.7, 48.8, 
60.7 and 81.8%, respectively), while the activity of 
SOD decreased (by 19.9%) and ribonuclease activity 
did not change significantly in comparison with intact 
group (table 7). 
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Table 7 
The influence of the combination enoxifol (7.5 mg/kg) + rexod (0.01 mg/kg) on the indices of the energy supply systems,  
the antioxidant defense and lysosomal activity in the ischemic skin (M ± m, n=8) 
Index Intact group 
Ischemic skin 
Control group Experimental group 
ATP, µM/g 14.2 ± 0.2 2.9 ± 0.2
*****
 
(-79.6) 
3.5 ± 0.2
*****
 
-75.4/20.7 
ADP, µM/g 1.9 ± 0.3 
 
2.0 ± 0.2 
(5.3) 
1.9 ± 0.2 
0.0/-5.0 
AMP, µM/g 0.6 ± 0.1 0.8 ± 0.1 
(33.3) 
0.7 ± 0.1 
16.7/-12.5 
АТP/АМP 2.2 ± 0.2 1.45 ± 0.13
***
 
(-34.1) 
1.8 ± 0.2 
-18.2/24.1 
AP, µM/g  4.4 ± 0.2 2.9 ± 0.1
*****
 
(-34.1) 
3.6 ± 0.2
**
 
-18.2/24.1 
Cytochrome С, µM/mg 1.08 ± 0.1 0.85 ± 0.10 
(-21.3) 
0.90 ± 0.08 
-16.7/5.9 
Coenzyme Q10, mcg/g  1610.0 ± 47.0 1025.0 ± 34.0***** 
(-36.3) 
1340.0±41.0*****
 
-16.8/30.7 
Pyruvate, mcg/g 5.6 ± 0.2 6.0 ± 0.2 
(7.1) 
5.8 ± 0.2 
3.6/-3.3 
Lactate / Pyruvate 73.0 ± 15.0 102.0 ± 10.0 
(39.7) 
85.0 ± 8.0 
16.4/-16.7 
SDH, mcg of formazan /mg of protein 
 min 
6.8 ± 0.3 5.9 ± 0.2* 
(-13.2) 
6.0 ± 0.2* 
-11.8/1.7 
NAD·H-cytochrome of C-reductase,  
nM of ferrocytochrome/mg per min 
82.0 ± 12.0 59.0 ± 3.0 
(-28.0) 
69.0 ± 6.0
 
-15.9/16.9 
NАD
+
, µM/g 3.0 ± 0.3 2.4 ± 0.2 
(-20.0) 
2.8 ± 0.2 
-6.7/16.7 
NАD H, µM/g 2.72 ± 0.15 2.4 ± 0.11 
(-11.8) 
2.7 ± 0.1 
-0.7/12.5 
NАD
+
/ NАD H 1.10 ± 0.13 1.0 ± 0.1 
(-9.1) 
1.04 ± 0.05 
-5.5/4.0 
NАD
+
/ NАD H, 
 µmol/g 
5.72 ± 0.27 4.8 ± 0.17** 
(-16.1) 
5.5 ± 0.2
 
-3.8/14.6 
RFO
2-
, µM/mg of protein  min 28.0 ± 4.0 80.0 ± 10.0***** 
(185.7) 
41.0 ± 8.0

 
46.2/-48.8 
SOD, U/g of protein 37.2 ± 2.7 29.8 ± 2.1* 
(-19.9) 
39.4 ± 1.4
 
5.9/32.2 
Catalase, nM Н2О2/mg of protein  
min 
80.0 ± 10.0 119.0 ± 12.0* 
(48.8) 
98.0 ± 7.0 
22.5/-17.6 
Cathepsin D, mcg of  tyrosine/mg of 
protein per min 
2.8 ±0.2 4.5 ± 0.4**** 
(60.7) 
3.0 ± 0.2
 
7.1/-33.3 
Ribonuclease, mcg/mg of protein per 
min 
1.2 ± 0.2 1.8 ± 0.2 
(50.0) 
1.2 ± 0.2
 
0.0/-33.3 
ALP, nM/mg of protein per min 2.2 ± 0.3 4.0 ± 0.4*** 
(81.8) 
2.8  ± 0.2
 
27.3/-30.0 
*р < 0.05, **р < 0.02, ***р < 0.01,****р < 0.002, *****р < 0.001 in comparison with intact group; 

р < 0.02, 

р < 0.01,
 
р < 
0.002, 

р < 0.001 in comparison with control group. 
 
Intraperitoneal administration of the combination 
enoxifol (7.5 mg/kg) + rexod (0.01 mg/kg) statistically 
significantly decreased the RFO
2-
, activity of the 
cathepsin D and ALP (48.8, 33.3, and 30.0%, 
respectively) in the ischemic skin homogenates of the 
experimental group of animals in comparison with 
control group, while the activity of SOD increased (by 
32.2%); activity of the catalase and ribonuclease did not 
change significantly (table 7). 
 
Conclusions 
1. Against the background of the ischemia of the 
rat tail tissues, induced by the occlusion of most of its 
blood vessels, and skin ischemia, induced by sewing 
of the skin fold of the back, the combination of 
enoxifol with rexod in single and, increasingly, 
repeated (for 7 days) intravenous administration has a 
more pronounced histoprotective effect than enoxifol 
and rexod, taken as reference drugs. 
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2. Against the background of the arterial 
insufficiency and venous stasis of the skin flap of the 
anterior abdominal wall of rats induced by occlusion 
(of the left side) of the celiac artery and vein, 
dermatoprotective activity of enoxifol, rexod, 
alprostadil and its combination as single and repeated 
(for 7 days) intravenous administration can be 
arranged in the following descending range: enoxifol 
+ alprostadil > alprostadil > enoxifol + rexod> 
enoxifol > rexod. 
3. Repeated (for 14 days) intravenous 
administration of enoxifol with rexod to rats with 
experimental diabetes mellitus complicated with 
exogenous hypercholesterinemia, has more 
pronounced dermatoprotective activity (on the skin 
flap of the anterior abdominal wall) than the 
administration of this combination against the 
background of normoglycemia. The combination of 
enoxifol with rexod decreases the level of blood 
glucose as under the condition of normoglycemia, as 
experimental diabetes mellitus and exogenous 
hypercholesterolemia; it causes a decrease the 
concentration of total cholesterol, triglycerides, β-
lipoproteins and increasing of the high density 
lipoproteins; it has no significant effect on lipid 
parameters under the condition of normoglycemia. 
4. Under the conditions of normoxia and 
hypoxia, induced by sodium cyanide, uncoupling of 
oxidative phosphorylation, induced by 2,4-
dinitrophenol, enoxifol, rexod and its combinations 
are capable of, in the first case, to increase the 
viability of cultured osteoblasts, and in the second 
case, as osteoblasts, as fibroblasts of rats. 
5. Enoxifol has anti-inflammatory action on 
edema, caused by histamine, serotonin and, to a 
greater extent, carageenan and Freund's complete 
adjuvant, but compare poorly of peroxicam and 
indomethacin. The mechanism of antiphlogogenic 
action of enoxifol may be due to the inhibitory effect 
of it on a prostaglandin phase of exudation and the 
phase of arachidonic acid metabolism, realized by 5- 
lipoxygenase way. 
6. Under the condition of steroid gastric ulcers in 
rats enoxifol, rexod and, especially, its combination 
possess antiulcer action, enoxifol activity compare 
poorly of the sea buckthorn oil; the combination of 
enoxifol with rexod is much superior as enoxifol, 
rexod and sea buckthorn oil taken from separately. 
7. The combination of enoxifol with rexod has a 
more significant positive influence on energy 
processes and antioxidant system that is increasing 
the efficiency of mitochondrial oxidation, decreasing 
the level of products of free radical oxidation in 
ischemic tissues, increasing the energy potential and 
stabilizing membrane structures of cells than 
separately administrated enoxifol and rexod. 
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